Trade News
Rotkreuz/Switzerland, 17. November 2009
Roche announces the 6000th installation of the cobas® 6000 analyzer series
The cobas® 6000 analyzer series has strengthened Roche’s leading position in the in vitro diagnostics market by satisfying the unmet needs of the clinical laboratory. Launched in 2006 the compact and reliable platform has achieved rapid market acceptance in mid to high workload laboratories by offering the full consolidation of clinical chemistry and immunoassay testing. The installation of the 6000th cobas 6000 module makes Roche’s system one of the most successful Serum Work Area solutions in recent years.
Customer events are planned for Australia, Brazil, China, Turkey and the United States, where installations of the cobas 6000 analyzer series have generated considerable momentum. Yet customer satisfaction is truly global. “For us, this concept is very attractive, we are a medium sized laboratory and the cobas 6000 analyzer is the ideal solution,” said Dr. Jos Pouwels, The Netherlands. Pier Mario Gerthoux, Italy, states: “We looked at the competition, but we felt that Roche has the best system.”
Exceeding expectations
Why is the cobas 6000 analyzer series so successful? For James Linehan, Marketing Manager at Roche, the reason is clear: “It’s the only product in its class capable of performing 200 of the most important diagnostic tests on one system. Consequently, laboratories require less blood from patients, and physicians receive critical test results much faster – two powerful factors in lowering costs and improving patient outcomes.”
Just as every patient requires individualized care, every laboratory is unique. Striking the balance between high clinical standards and efficient operation requires innovative solutions. “Starting with the cobas 6000 analyzer series, Roche has developed a system platform that can be tailored to the individual needs of the laboratory,” said Ann Costello, Head of Roche Serum Work Area Solutions. “The tremendous success of the cobas 6000 analyzer series gives us confidence to launch other important elements of our platform, such as the cobas 8000 modular analyzer series* for high workload laboratories.”
The cobas 6000 analyzer series is part of a larger solution, which enhances testing efficiency in laboratories. Combined with MODULAR PRE-ANALYTICS for sample preparation and middleware platforms for data management, the solution is designed to automate many of the manual processes, helping laboratories to further simplify their operation and improve the quality of patient results.
About the cobas 6000 analyzer series
One platform, seven configurations: The cobas 6000 analyzer series offers hospital and commercial laboratories reliable 24-hour operation and the ability to grow without significant investment.
- Full consolidation of over 200 diagnostic tests
- High flexibility with scalable system configurations
- Unique reagent concept with highly stable, ready-to-use reagents
- ECL immunoassay technology
- Critical care results in as little as 9 minutes
- Seamless integration of automated sample preparation and data management
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are legally protected.
* The cobas 8000 modular analyzer series is not yet available in the US.